Removal of Syrups from Schedule K: Strengthening Drug Regulation and Public Health Safety in India

Recent Developments:

• The Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 by removing the term “Syrups” from Schedule K, thereby ending the exemption previously available to syrup-based medicines.
• As a result, cough syrups and other medicinal syrups can now be sold only through licensed pharmacies under stricter regulatory oversight, particularly in rural areas where exemptions earlier existed.
• The decision follows international concerns regarding contaminated cough syrups linked to child fatalities in several countries since 2022, which intensified scrutiny of India's pharmaceutical regulatory framework.
• The measure is intended to improve traceability, accountability, quality control and responsible dispensing of medicines while reducing unsafe self-medication practices.

Background of the Issue:

Why was the Amendment Necessary?

• Several incidents involving cough syrups contaminated with toxic industrial solvents such as Diethylene Glycol (DEG) and Ethylene Glycol (EG) resulted in deaths of children in multiple countries, raising serious concerns regarding pharmaceutical quality assurance.
• The incidents attracted global attention because India is one of the world's largest suppliers of generic medicines and pharmaceutical products.
• The controversy highlighted weaknesses in manufacturing oversight, supply-chain monitoring and regulatory enforcement mechanisms.
• The amendment seeks to strengthen public confidence in Indian pharmaceutical products and protect India's reputation as a major global medicine supplier.

India’s Pharmaceutical Sector:

Global Importance of the Sector:

• India is widely referred to as the “Pharmacy of the World” because of its ability to supply affordable and quality-assured medicines to numerous countries.
• India possesses the largest number of United States Food and Drug Administration (USFDA) approved pharmaceutical manufacturing facilities outside the United States.
• The country plays a critical role in global health security by supplying vaccines, generic medicines and essential pharmaceutical products.
• India accounts for nearly 20% of the global supply of generic medicines by volume and is among the leading vaccine producers globally.
• The pharmaceutical industry contributes significantly to exports, employment generation and healthcare accessibility.

Active Pharmaceutical Ingredient (API) Ecosystem:

• India hosts nearly 500 Active Pharmaceutical Ingredient (API) manufacturers.
• The country contributes approximately 8% of global API production.
• APIs constitute the biologically active component responsible for the therapeutic effect of medicines.
• Strengthening domestic API manufacturing has become a strategic priority under initiatives such as Production Linked Incentive (PLI) Scheme and Bulk Drug Parks Scheme.

Schedule K under Drugs Rules, 1945:

Meaning and Purpose:

• Schedule K contains a list of drugs exempted from certain provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, subject to specified conditions.
• The schedule was designed to facilitate easier access to selected medicines where strict licensing requirements were considered unnecessary.
• Certain medicines under Schedule K could be sold through specified channels under relaxed regulatory conditions.
• The exemption was particularly useful in remote and sparsely populated areas lacking adequate pharmacy infrastructure.

Implications of Removing Syrups from Schedule K:

• Syrup formulations are no longer eligible for Schedule K exemptions.
• Their sale, storage and dispensing now fall under stricter regulatory requirements.
• Distribution of cough syrups in villages and smaller settlements must occur through licensed pharmacies.
• The amendment enhances accountability throughout the supply chain and improves regulatory oversight.

Regulatory Framework Governing Drugs in India:

Central Drugs Standard Control Organization (CDSCO):

• CDSCO is India's national regulatory authority responsible for ensuring the safety, efficacy and quality of drugs.
• It functions under the Ministry of Health and Family Welfare.
• The organization is headed by the Drugs Controller General of India (DCGI).
• CDSCO regulates approval of new drugs, clinical trials, imports and central licensing activities.

Drugs and Cosmetics Act, 1940 and Related Rules:

• The Drugs and Cosmetics Act, 1940 forms the foundation of pharmaceutical regulation in India.
• It regulates the import, manufacture, sale and distribution of drugs and cosmetics.
• Important subordinate regulations include:
• Drugs Rules, 1945.
• Medical Devices Rules, 2017.
• New Drugs and Clinical Trials Rules, 2019.
• Cosmetics Rules, 2020.

National Pharmaceutical Pricing Authority (NPPA):

• NPPA regulates prices of essential medicines under the Drugs (Prices Control) Order, 2013.
• It ensures affordability and availability of essential medicines.
• It monitors compliance with government pricing policies.

Indian Pharmacopoeia Commission (IPC):

• IPC publishes the Indian Pharmacopoeia, which serves as the official compendium of drug standards in India.
• The Pharmacopoeia prescribes standards relating to identity, purity, quality and strength of medicines.
• Compliance with Pharmacopoeial standards is essential for ensuring drug quality and safety.

State Licensing Authorities (SLAs):

• Manufacturing, sale and distribution of drugs are regulated through a licensing system administered by State Licensing Authorities.
• State drug regulators conduct inspections, licensing and enforcement activities within their respective jurisdictions.
• The Indian regulatory structure follows a dual model involving both Union and State governments.

Concerns Regarding India’s Pharmaceutical Regulatory Ecosystem:

Manufacturing Quality Challenges:

• Cases of contamination, substandard medicines and manufacturing lapses indicate weaknesses in compliance with Good Manufacturing Practices (GMP).
• Inadequate quality assurance systems can undermine patient safety and international confidence.

Fragmented Regulatory Oversight:

• Different enforcement capacities across States create variations in regulatory effectiveness.
• Uneven implementation of standards may result in regulatory gaps.

Over-the-Counter Drug Culture:

• Self-medication remains widespread across India.
• Unsupervised consumption of medicines can lead to adverse effects, antimicrobial resistance and irrational drug use.
• Easy availability of medicines often discourages professional medical consultation.

Capacity Constraints in State Drug Regulation:

• Several State drug control departments face shortages of inspectors, laboratories and technical experts.
• Limited infrastructure reduces the frequency and effectiveness of inspections.
• Rapid growth of the pharmaceutical sector has increased the burden on regulatory agencies.

Recent Reforms and Regulatory Strengthening Measures:

State Health Regulatory Excellence Index (SHRESTH):

• SHRESTH is a national initiative designed to benchmark and strengthen State-level drug regulatory systems.
• The framework promotes transparency, accountability and evidence-based performance assessment.
• The initiative encourages States to improve regulatory infrastructure and governance standards.

Enhanced Manufacturing Surveillance:

• Following contamination incidents, regulatory authorities increased inspections of pharmaceutical manufacturing facilities.
• Greater emphasis has been placed on compliance with quality standards and corrective action mechanisms.
• Risk-based inspections are increasingly being adopted to improve regulatory efficiency.

Way Forward:

Strengthening Pharmaceutical Governance:

• Quality assurance systems should be integrated throughout the manufacturing lifecycle rather than relying solely on final product testing.
• Regulatory agencies should adopt risk-based inspections, digital monitoring and continuous quality surveillance.
• Public disclosure of inspection findings and enforcement actions can improve transparency and accountability.
• Harmonisation of regulatory standards across States is necessary for uniform enforcement.

Leveraging Technology for Drug Regulation:

• Artificial Intelligence (AI) and advanced data analytics can improve detection of quality risks.
• Digital supply-chain tracking systems can enhance traceability and recall mechanisms.
• Real-time monitoring platforms can strengthen regulatory responsiveness.
• Integrated databases can facilitate coordination among central and state regulatory authorities.

Value Addition for UPSC:

Important Terms:

• Schedule K: List of drugs exempted from specific provisions of the Drugs Rules, 1945 under prescribed conditions.
• CDSCO: National regulatory authority responsible for drug approval and quality regulation.
• DCGI: Head of CDSCO and India's chief drug regulatory authority.
• API: Active component responsible for the therapeutic action of a medicine.
• NPPA: Authority responsible for regulation of drug prices.
• IPC: Institution responsible for publishing standards for medicines marketed in India.
• Good Manufacturing Practices (GMP): Quality assurance standards governing pharmaceutical manufacturing.
• SHRESTH: National framework for evaluating and strengthening State drug regulatory systems